Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

GENERIC MFR. BOLAR IS ONLY STRONG PERFORMER AS ALL COMPONENTS DROP

  • News

Executive Summary

GENERIC MFR. BOLAR IS ONLY STRONG PERFORMER AS ALL COMPONENTS DROP Generic mfr. Bolar (up 2-1/2 to 22-1/2) was the only issue on the "F-D-C" Index to post a strong gain as all components lost ground during the week ended March 9. After Bolar, the best weekly performances were turned in by Pennwalt (up 3/4 to 37-1/4), Upjohn (up 3/4 to 58-5/8), and Searle (up 5/8 to 47-1/4). Overall only eight stocks advanced, while 41 declined and four remained unchanged. Hospital supply stocks continued to perform poorly as American Hospital Supply fell 2-1/2 to 34-1/4, and Baxter slipped 7/8 to 17. On Wednesday Baxter hit a low 16-3/8. Abbott remained unchanged for the week at 40-3/8. Jack Eckerd (up 1/8 to 25-1/2) was the only chain to advance on the week. Chart omitted.

Table

View full table

Tags:
Latest Headlines

Mismatch Between Growing Vaccine Pipeline and CDC’s ACIP Capacity

Keeping Track: Two Breakthrough Oncologics, Another Antibiotic Clear US FDA Along With Pfizer’s Hemophilia B Gene Therapy

Priority Review Vouchers: Tropical Disease Candidates Wait Years For FDA Action On Qualifying List

Pink Sheet Podcast: US FDA Biosimilar Strategy, Gene Therapy Accelerated Approvals, FDA v. Partisan Politics

See All
UsernamePublicRestriction

Register

PS006258

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By